Press Releases

Date	Title
November 29, 2021	Outlook Therapeutics Announces Closing of $57.5 Million Bought Deal, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares ISELIN, N.J. , Nov. 29, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today
November 23, 2021	Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $50 Million ISELIN, N.J. , Nov. 23, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications,
November 23, 2021	Outlook Therapeutics Announces $10 Million Bought Deal Offering of Common Stock ISELIN, N.J. , Nov. 23, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced
November 13, 2021	Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference - NORSE TWO showed highly statistically significant, clinically relevant results consistent with historical ophthalmic bevacizumab data - Data support planned BLA submission with U.S. FDA in Q12022 ISELIN, N.J. , Nov. 13, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.
November 10, 2021	Outlook Therapeutics to Present at the Virtual Investor Roundtable Event Live moderated video webcast discussion among members of management and Thought Leaders Firas M. Rahhal, MD and Robert L. Avery, MD on Tuesday, November 16th at 9:00 AM ET ISELIN, N.J. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working
November 4, 2021	Outlook Therapeutics to Present at the Retina Subspecialty Day, American Academy of Ophthalmology 2021 Annual Conference Firas M. Rahhal, MD, will present Phase 3 pivotal data from the NORSE TWO registration trial on Saturday, November 13, 2021 ISELIN, N.J. , Nov. 04, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved
November 3, 2021	Outlook Therapeutics to Present at the Eyecelerator@AAO 2021 Conference Retina Showcases Outlook Therapeutics management to present on Thursday, November 11, 2021 ISELIN, N.J. , Nov. 03, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in
October 12, 2021	Outlook Therapeutics’ Positive NORSE THREE Safety Data Presented at 2021 American Society of Retina Specialists for ONS-5010 Ophthalmic Bevacizumab Strong safety data from NORSE THREE registration trial consistent with other trials for ONS-5010 and in prior published research ISELIN, N.J. , Oct. 12, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first
October 7, 2021	Outlook Therapeutics to Present at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting Suber Huang, MD, MBA, FASRS, will present safety data from Outlook Therapeutics’ NORSE THREE registration trial on Tuesday, October 12, 2021 ISELIN, N.J. , Oct. 07, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the
October 5, 2021	Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase Outlook Therapeutics senior leadership team to provide a company overview and participate on industry panel on Thursday, October 7, 2021 ISELIN, N.J. , Oct. 05, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first